U.S. markets close in 3 hours 52 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
20.03+0.06 (+0.30%)
As of 12:08PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close19.97
Open19.50
Bid20.05 x 1100
Ask20.08 x 900
Day's Range19.48 - 20.32
52 Week Range12.20 - 31.18
Volume466,940
Avg. Volume541,259
Market Cap2.336B
Beta (5Y Monthly)0.72
PE Ratio (TTM)25.68
EPS (TTM)0.78
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
4% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
    Zacks

    Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1

    Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.

  • Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
    Benzinga

    Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients

    Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced interim data from the Phase 2 trial evaluating its selective cortisol modulator miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). The company had to suspend the trial after most patients who received the therapy had elevated liver enzymes. “When we observed elevated ALT and AST levels in four of the first five patients who received miricorilant for four weeks, we suspended the study,” commented Dr. Andreas Grauer Corcept’s Chief Medical Officer. ALT and AST are liver enzymes, and their elevations indicate the inflammation or injury to liver cells. The rise in enzymes was resolved after miricorilant was withdrawn, the company said. Around 30% reduction in liver fat at week 12 was the primary endpoint of the trial for which the company targeted to enroll 120 patients. “These patients exhibited much larger reductions after receiving miricorilant for 4-6 weeks,” Grauer added. “Liver fat reductions achieved this quickly and of this magnitude are rarely seen,” noted Dr. Stephen A. Harrison, the lead investigator of the study. He called for further research to see if miricorilant can significantly and safely reduce liver fat with a meaningful improvement in NASH. Price Action: CORT shares closed 0.2% lower at $21.71 on Thursday. See more from BenzingaClick here for options trades from BenzingaCigna's Strong Performance Across Businesses Drive Q1 Earnings Beat; Raises 2021 GuidanceAdcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.